Oropharyngeal Care With Colostrum, Chlorohexidine and Sodium Bicarbonate in Preventing Ventilator-associated Pneumonia in Preterm Neonates
Comparative Study of Oropharyngeal Care With Colostrum, Chlorohexidine and Sodium Bicarbonate in Preventing Ventilator-associated Pneumonia in Preterm Neonates
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tanta, Egypt
- Neonatal Intensive Care Unit, Tanta University Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Preterm neonates with gestational age less than 37 weeks. Neonates admitted to the Neonatal Intensive Care Unit (NICU). Neonates requiring invasive mechanical ventilation for more than 48 hours. Age ≤ 72 hours at time of enrollment. Written informed consent obtained from parents or legal guardians.
Exclusion Criteria:
- Neonates with major congenital anomalies. Neonates with congenital airway malformations. Presence of congenital pneumonia at birth. Neonates with severe gastrointestinal malformations preventing enteral feeding. Neonates who develop early-onset sepsis at admission. Neonates with contraindications to oral care procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Colostrum Group
Preterm neonates receiving oropharyngeal care with expressed maternal colostrum applied to the oral mucosa using sterile swabs at regular intervals during mechanical ventilation.
|
Application of small amounts of expressed maternal colostrum to the oral mucosa of ventilated preterm neonates using sterile swabs every 3-4 hours according to NICU oral care protocol.
|
|
Experimental: Chlorhexidine Group
Preterm neonates receiving oropharyngeal care using diluted chlorhexidine solution applied to the oral cavity using sterile swabs.
|
Oropharyngeal care using diluted chlorhexidine solution applied to the oral cavity of ventilated preterm neonates at scheduled intervals according to NICU protocol.
|
|
Experimental: Sodium Bicarbonate Group
Preterm neonates receiving oral care using sodium bicarbonate solution applied to the oral mucosa using sterile swabs.
|
Preterm neonates receiving oral care using sodium bicarbonate solution applied to the oral mucosa using sterile swabs.
|
|
Experimental: Control Group (Normal Saline)
Preterm neonates receiving routine oral care using sterile normal saline.
|
Routine oropharyngeal care using sterile normal saline applied with sterile swabs at regular intervals during mechanical ventilation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Ventilator-Associated Pneumonia (VAP)
Time Frame: Up to 28 days after initiation of mechanical ventilation.
|
To compare the incidence of ventilator-associated pneumonia among preterm neonates receiving different types of oropharyngeal care (colostrum, chlorhexidine, sodium bicarbonate, or normal saline).
Diagnosis of VAP will be based on clinical signs, radiological findings, and microbiological evidence according to NICU infection
|
Up to 28 days after initiation of mechanical ventilation.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
1.Time to Development of Ventilator-Associated Pneumonia
Time Frame: From initiation of mechanical ventilation up to 28 days.
|
Time interval between initiation of mechanical ventilation and the first diagnosis of ventilator-associated pneumonia.
|
From initiation of mechanical ventilation up to 28 days.
|
|
2.Duration of Mechanical Ventilation
Time Frame: From initiation of mechanical ventilation until successful extubation, up to 28 days.
|
Total duration of invasive mechanical ventilation required by preterm neonates in each study group.
|
From initiation of mechanical ventilation until successful extubation, up to 28 days.
|
|
3. Length of Neonatal Intensive Care Unit (NICU) Stay
Time Frame: From NICU admission until discharge, up to 60 days.
|
Total number of days the neonate remains admitted in the NICU.
|
From NICU admission until discharge, up to 60 days.
|
|
4.Neonatal Mortality
Time Frame: From NICU admission until discharge, up to 60 days
|
All-cause mortality among ventilated preterm neonates during NICU hospitalization.
|
From NICU admission until discharge, up to 60 days
|
|
5. Oropharyngeal Bacterial Colonization
Time Frame: Baseline and up to 28 days after initiation of mechanical ventilation.
|
Presence and type of bacterial colonization detected in oropharyngeal swab cultures among ventilated preterm neonates.
|
Baseline and up to 28 days after initiation of mechanical ventilation.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dalia Ayoub, Tanta University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 36264MS499/2/24
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventilator-Associated Pneumonia
-
NCT05589727CompletedHealthcare-Associated Pneumonia | Ventilator-Associated Pneumonia | Healthcare Associated Infection
-
NCT00610324CompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated Pneumonia
-
NCT02070757CompletedLung Diseases | Healthcare-Associated Pneumonia | Ventilator-Associated Pneumonia
-
NCT00543608TerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
NCT02779933CompletedVentilator-Associated Pneumonia
-
NCT06118242Not yet recruitingVentilator-Associated Pneumonia
-
NCT03581370Recruiting
-
NCT02440828CompletedVentilator Associated Pneumonia (VAP)
-
NCT04038814CompletedVAP - Ventilator Associated Pneumonia
-
NCT02897466Unknown
Clinical Trials on Oropharyngeal Care with Colostrum
-
NCT06459414Completed
-
NCT05481866Not yet recruitingGut Microbiota | Metabolites
-
NCT01536093CompletedPremature Infant | Extremely Low Gestational Age Newborn
-
NCT07129668Completed
-
NCT02284178Completed
-
NCT07397221Not yet recruitingCoronary Artery Bypass
-
NCT05877625Active, not recruitingVentilator-associated Pneumonia | Hospital Acquired Infection
-
NCT06812403CompletedHypoxia | Gastric Cancer | Esophageal Cancer | Polyp of Colon